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Summary Monoclonal antibody TFS-4 has previously been shown to react selectively with human small cell
lung cancer (SCLC). We evaluated the use of 1311-labelled TFS-4 for the treatment of established human
SCLC transplanted in nude mice. The specific accumulation of the antibody in the transplanted tumour was
recorded by both scintigraphic and biodistribution studies. Administration of 200pCi 131 I-labelled TFS-4
inhibited tumour growth when compared with the same radiation dose of the control monoclonal antibody.
The therapeutic effect was dose-dependent and complete disappearance of the tumour was observed
transiently in one out of the three animals following the administration of 500pCi 131 I-labelled TFS-4.
The efficacy of radiotherapy for small cell lung cancer
(SCLC) is limited although the tumour cells are usually
radiosensitive. This is because SCLC is considered essentially
a systemic disease since the tumour rapidly infiltrates over
the radiation field and quickly metastasises to distant organs.
One possible method for overcoming this situation is the
utilisation of a monoclonal antibody as a carrier to deliver
radioactive particles to the radiosensitive tumour.
A monoclonal antibody, TFS-4, which specifically reacts
with SCLC, has already been developed (Okabe et al., 1984).
It was demonstrated that TFS-4 did not bind to a variety of
normal or other malignant cells except for neuroendocrine or
APUD cells (Watanabe et al., 1987a,b). We subsequently
studied the use of TFS-4 as an 1311 carrier for the diagnosis
of SCLC. Since '311-labelled TFS-4 administered i.v. selecti-
vely accumulated in tumour tissue which had been trans-
planted into a nude mouse, a gamma scintillation camera
depicted the clearly-demarcated tumour figure (Okabe &
Takaku, 1986). As beta-emitter, 1311 also has strong destruc-
tive power to nearby cells. It was therefore surmised that
131I-labelled TFS-4 could be applied to the treatment of
SCLC. This paper reports the antitumour effect of 1311-
labelled TFS-4 on human SCLC transplanted in nude mice.
Materials and methods
Monoclonal antibodies
The production of TFS-4 (Okabe et al., 1984) is summarised
as follows: hybridoma cells secreting monoclonal antibody
TFS-4 were produced by fusion of P3X63Ag8Ul mouse
myeloma cells and spleen cells from BALB/c mice immu-
nised against SCLC tumours grown in BALB/c nude mice.
TFS-4 is a murine IgGI antibody which recognises the
antigen of SCLC cell surface protein with a molecular weight
of 124,000 (Okabe et al., 1984; Watanabe et al., 1987b).
As an irrelevant control antibody, a murine IgGI monoc-
lonal antibody reactive with human recombinant interferon
gamma was prepared.
Ascites containing a high-titer monoclonal antibody were
produced by injecting hybrid cells (1 x 107) i.p. into BALB/c
mice primed with tetramethylpentadecane (Wako Pure Che-
mical Industries Ltd., Osaka, Japan). The monoclonal anti-
bodies were purified from the ascites by ammonium sulphate
precipitation and ion exchange chromatography on
Zetaprep-15 DEAE Discs (AMF Ltd.).
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Iodination of monoclonal antibodies
The antibodies were iodinated with 1311 using chloramine-T
(Greenwood et al., 1963). One ml of an antibody
(0.5mgml-1 in 10mM PBS, pH7.4) was mixed with 25 il
1311 as sodium iodide (370MBq, Amersham, 10mCi, code
IBS30) and 100p1 chloramine-T (1 mgml-1). After incuba-
tion for min, 100Ml Na-metapyrosulphate (2mgml-1) was
added to the solution to stop the reaction. Free iodine was
removed by gel filtration using a G-25 Sephadex column
equilibrated with PBS containing 0.2% bovine serum albu-
min. The labelling yield was -40% with a specific activity
of 3-7mCimg-1.
Animal xenograft models
Two human small cell carcinoma cell lines, TNSC-1 (Okabe
et al., 1984) and NCI-H69 (Gazdar et al., 1980), and an
adenocarcinoma cell line, HLC-2 (Okabe et al., 1984) were
used to produce tumour xenografts in female BALB/c nude
mice (4-6 weeks old). TNSC-1 and HLC-2 were established
in our laboratory. Cells (3 x 106-3 x 107) were implanted s.c.
in the back of a nude mouse. Heterotransplants of nude
mouse tumours were histologically and functionally similar
to the patients' tumours (Okabe et al., 1984). Two or three
weeks after the inoculation, when diameter of the tumour
nodule, being in the exponential growth stage, reached 0.5-
1.0cm, the animal was injected i.p. with a monoclonal
antibody solution. Tumour size was measured with calipers
every 3-4 days and tumour volume estimated using the
following formula
Volume =(x/6) x Length x Width2
Scintigraphy and biodistribution
Seventy pCi of 1311-labelled TFS-4 was injected i.v. into
nude mice 3 weeks after implantation of TNSC-1 cells on
both sides of the back of animals. Scintillation imaging was
carried out at 1, 2, 4 and 7 days after injection. The mice
were anaesthetised by i.p. injection of pentobarbital and
attached to boards with adhesive tape. Imaging was obtained
externally in a posterior projection using a gamma scintilla-
tion camera with a pinhole collimator.
Seven days after i.p. injection of 100,uCi 131I1-labelled
TFS-4, the animals were killed and the amount of radio-
activity in each organ assessed using a gamma counter.
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Figure 1 TNSC-1 tumour cells were implanted on both sides of
the back of a nude mouse. The posterior image of a mouse was
obtained one (a), two (b), four (c) and seven days (d) after a
70pCi injection 131I-labelled TFS-4. On day four (c), specific
antibody localisation was noted in the tumour. After 7 days the
tumour figure was even more clearly demarcated (d).
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Figure 2 Distribution of radioactivity in nude mice bearing
human SCLC (TNSC-1). Tissue-to-blood ratios of radioactivity 7
days after 100MCi injection 13II-labelled TFS-4 were measured in
4 animals.
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Figure 3 Antitumour effect of various doses of 1311-labelled
TFS-4 on SCLC (TNSC-1) transplanted in nude mice. Groups of
3 animals bearing xenografts of 5-10mm in diameter were
injected with 50QpCi (0), 300yCi (0), 100pCi (A) or OpCi (no
injection; A) of 1311-labelled TFS-4. The mean percentage
changes in tumour volume are compared between the groups.
Injection of300-500uCi led to a significant (P<0.01 by Student's
t test) inhibition of tumour growth compared to 0-100pCi.
Results
Antibody localisation
Twenty-four hours after injection of 131I-labelled TFS-4,
gamma scintigraphy showed whole-mouse figures without
tumour contours. Four days after injection, the tumours
were clearly imaged. On day 7, tumours were even more
clearly demarcated, with decreased background radio-
activity (Figure 1).
Specific accumulation of radioactivity in the tumour tissue
was also demonstrated by biodistribution. Figure 2 shows
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Figure 4 Specificity of 1311-labelled TFS-4. Groups of 4 or 5
animals bearing TNSC-1 were treated with one of three agents.
Tumour growth was inhibited by 200,uCi 1311-labelled TFS-4
(0) compared with the equivalent protein dose of unlabelled
TFS-4 (0; P<0.05) and with 200 Ci 13II-labelled control
monoclonal antibody (A; P<0.01).
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Figure 6 Tumour response to repeated injection of 131I-labelled
TFS-4. A group of 3 animals bearing TNSC-l xenografts were
injected twice (days 0 and 35: arrows) with 500tuCi 131I-labelled
TFS-4 (@). The change in tumour volume was followed over 79
days. The change in untreated xenografts is shown as a control
(0).
(Figure 5). Compared with the adenocarcinoma, tumour
growth in one SCLC (NCI-H69) was significantly inhibited,
while growth in the other SCLC (TNSC-1) was apparently
inhibited only for a short period.
Days
Figure 5 Antitumour effect of 1311I-labelled TFS-4 on various
lung cancers. Groups of 4 or 5 animals bearing one of three lung
cancers were treated with 200,uCi 1311-labelled TFS-4. Tumour
growth was not significantly inhibited in one SCLC, TNSC-1
(0; P >0.05), but appeared to be inhibited in the other, NCI-
H69 (A; P<0.05), compared with an adenocarcinoma, HLC-2
(0).
the distribution of radioactivity in 4 animals on day 7 after
injection of 131I-labelled TFS-4. The concentration of
radioactivity in the tumour tissue (TNSC-1) was higher than
that in the normal tissues. The tumour-to-blood radioactivity
ratio was 4.33 + 1.60 (mean +s.e.). The ratios ofthe tumour to
the normal tissues other than blood were >8: 1. Radio-
activity in the brain was extremely low probably due to the
blood-brain barrier. When 1311-labelled anti-gamma inter-
feron antibody, which is not specific to SCLC, was injected
as a control, radioactivity levels in the tumour and normal
tissues were closely similar.
Effect on SCLC
Dose dependency of the therapeutic effect of 131I-labelled
TFS-4 on SCLC xenografts in nude mice is shown in Figure
3. Groups of 3 animals with TNSC-1 nodules of -0.5-
1.0cm in diameter were injected with varying doses of 1311.
labelled TFS-4. The original tumour sizes were equal
between the groups. Animals were observed over a 16-day
period. Injection of 300-500,yCi 131I-labelled TFS-4 led to a
marked inhibition of tumour growth compared to 0-)100pCi
1311-labelled TFS-4. The mean volume of tumours treated
with 500pCi 1311-labelled TFS-4 decreased to -60% of the
original, and the s.c. nodule disappeared transiently in one
of the three animals.
Figure 4 shows the effect of 200,uCi 131I-labelled TFS-4
on TNSC-1 in comparison to the two controls, i.e., the same
radiation dose of the control monoclonal antibody, and the
same protein dose of unlabelled TFS-4. It is clear that
tumour growth was inhibited by 131I-labelled TFS-4.
Effect on various lung cancers
The antitumour effect of 200pCi 1311I-labelled TFS-4 was
examined in three different lung cancers: two SCLCs
(TNSC-1 and NCI-H69) and an adenocarcinoma (HLC-2)
Repeated injection
131I-labelled TFS-4 (500pCi) was injected twice into animals
bearing TNSC-1 nodules with a 5-week interval. The tumour
volume was measured over a 79-day period; from initial
injection to the regrowth of tumour nodules. As is shown in
Figure 6, the second injection was as effective as the first
with tumour regression persisting for 14 days after each
injection although the nodules began to regrow thereafter, in
contrast to the rapid and steady growth of the untreated
nodules.
Discussion
Monoclonal antibodies offer a high potential for use in the
treatment as well as diagnosis of cancer. One of the most
promising applications is in a treatment strategy in which a
cytocidal radioisotope is conjugated with tumour-specific
monoclonal antibody.
Badger et al. (1985) studied a 131I-labelled monoclonal
antibody for treating established murine lymphoma. At a
dose of 500pCi, tumour nodules regressed in 44% of the
animals. Cheung et al. (1986) and Jones et al. (1985)
reported tumoricidal effects of a 131I-labelled monoclonal
antibody in nude mice xenografted with human neuroblas-
toma. Wakabayashi et al. (1984) clarified the antitumour
effects of 1311-labelled monoclonal antibodies in mice trans-
planted with murine melanoma. Clinically, Rosen et al.
(1987) treated patients with cutaneous T-cell lymphomas,
and Lashford et al. (1987) treated patients with neuroblas-
toma using a 1311-labelled monoclonal antibody. However,
radiolabelled monoclonal antibodies have not yet been exten-
sively applied to the treatment of human solid tumours
including lung cancer. One probable reason for this is the
lack of an antibody highly specific to such tumours, and
another is the low or modest radiosensitivity of most human
solid tumours. Accordingly, we should concentrate upon
SCLC, which is a heterogeneous tumour in which some of
the cells may be radiosensitive.
In the present study, we demonstrated a clear, dose-related
antitumour effect of 1311-labelled monoclonal antibody,
TFS-4, against human SCLC xenografts in nude mice.
Administration of 300pCi or more of the radiolabelled
antibody significantly inhibited growth of the xenografts
(Figure 3). Although mCi of the antibody seemed to be
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more effective, it resulted in a higher death rate probably
because of increased toxicity. The antitumour effect appears
to be achieved not only by high radiosensitivity of the
tumour, but also by the specific accumulation of 1311_
labelled TFS-4 in tumour tissues shown by scintigraphy-in
Figure 1 and by biodistribution in Figure 2. On the basis of
scintigram the tumour-absorbed dose from the 131I was
calculated to be 10.38 Gy, i.e., 9.99Gy by ,B beam and
0.39Gy by y beam. Unlabelled TFS-4 did not inhibit the
growth of SCLC xenografts (Figure 4). A murine IgGI
monoclonal antibody to human interferon, which was radio-
labelled with 1311, did not accumulate specifically into the
SCLC xenografts. Tumour growth was not inhibited by the
1311-labelled anti-interferon antibody. Although radiolabelled
TFS-4 inhibited tumour growth in two small-cell carcinomas,
it was ineffective against the adenocarcinoma of the lung
(Figure 5), which has previously been shown to be unreactive
with TFS-4 (Okabe et al., 1984; Watanabe et al., 1987a).
These observations suggest that the monoclonal antibody
TFS-4, which is specific for SCLC cells, can target therapeu-
tic doses of 1311 to human SCLC xenografts in nude mice.
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